Early investigational agents for the treatment of benign prostatic hyperplasia
Stamatios Katsimperis 1, Konstantinos Kapriniotis 2, Ioannis Manolitsis 1, Themistoklis Bellos 1, Panagiotis Angelopoulos 1, Patrick Juliebø-Jones 3 4, Bhaskar Somani 5, Andreas Skolarikos 1, Lazaros Tzelves 1 2
- 12nd University Department of Urology, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- 2Department of Urology, University College of London Hospitals (UCLH), London, UK.
- 3Department of Urology, Haukeland University Hospital, Bergen, Norway.
- 4Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- 5Department of Urology, University Hospital Southampton, Southampton, UK.
Affiliationer
Introduction: Benign prostatic hyperplasia (BPH), as a clinical entity that affects many people, has always been in the forefront of interest among researchers, pharmaceutical companies, and physicians. Patients with BPH exhibit a diverse range of symptoms, while current treatment options can occasionally cause adverse events. All the aforementioned have led to an increased demand for more effective treatment options.
Areas covered: This review summarizes the outcomes of new medications used in a pre-clinical and clinical setting for the management of male lower urinary tract symptoms (LUTS)/BPH and provides information about ongoing trials and future directions in the management of this condition. More specifically, sheds light upon drug categories, such as reductase‑adrenoceptor antagonists, drugs interfering with the nitric oxide (NO)/cyclic guanosine monophosphate (GMP) signaling pathway, onabotulinumtoxinA, vitamin D3 (calcitriol) analogues, selective cannabinoid (CB) receptor agonists, talaporfin sodium, inhibitor of transforming growth factor beta 1 (TGF-β1), drugs targeting the hormonal control of the prostate, phytotherapy, and many more.
Expert opinion: Clinical trials are being conducted on a number of new medications that may emerge as effective therapeutic alternatives in the coming years.
